Kirti Parwani

Kirti Parwani

Auto-generated profile, based on publicly available information

Kirti Parwani

P. D. Patel Institute of Applied Sciences, Charotar University of Science and Technology, Changa, Gujarat, India

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Mediators of Inflammation
Verified
Journal Article
Open access
HAHiral Aghara
Hiral Aghara
MPManali Patel
Manali Patel
PCPrashsti Chadha
Prashsti Chadha
KPKirti Parwani
Kirti Parwani
RCRuchi Chaturvedi
Ruchi Chaturvedi
PALASH MANDALPALASH MANDAL
PALASH MANDAL
The gut–liver–brain axis (GLB axis) plays a crucial role in maintaining metabolic, immune, and neurological homeostasis. The gut microbiota influences systemic health through its metabolites, including short‐chain fatty acids (SCFAs), bile acids (BAs), and tryptophan (Trp) derivatives, which regulate immune function, lipid metabolism, and neurotransmitter balance. Dysbiosis is an imbalance in gut microbiota that has been implicated in metabolic dysfuntion associated fatty liver disease (MAFLD), alcohol‐associated liver disease (AALD), and neuroinflammatory conditions such as schizophrenia. Increased gut permeability allows microbial byproducts like lipopolysaccharides (LPSs) to enter the liver and brain, activating inflammatory pathways that contribute to disease progression. Moreover, hepatic dysfunction can lead to neuroinflammation and cognitive impairments. Understanding the interplay between microbial metabolites and host physiology provides insight into novel therapeutic interventions. Strategies such as probiotics, prebiotics, synbiotics, fecal microbiota transfer (FMT), and postbiotics offer potential treatments to restore gut eubiosis and mitigate disease severity. This review highlights the mechanistic role of the GLB axis in health and disease, emphasizing microbiome‐targeted therapies as a promising avenue for managing metabolic and neuropsychiatric disorders. Trial Registration: ClinicalTrials.gov identifier: NCT04823676, NCT02496390, NCT06024681, NCT02721264

1 January 2021 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
FPFarhin Patel
Farhin Patel
KPKirti Parwani
Kirti Parwani
DPDhara Patel
Dhara Patel
PALASH MANDALPALASH MANDAL
PALASH MANDAL
Alcohol‐induced liver injury implicates inflammation and oxidative stress as important mediators. Despite rigorous research, there is still no Food and Drug Administration (FDA) approved therapies for any stage of alcoholic liver disease (ALD). Interestingly, metformin (Met) and several probiotic strains possess the potential of inhibiting alcoholic liver injury. Therefore, we investigated the effectiveness of combination therapy using a mixture of eight strains of lactic acid‐producing bacteria, commercialized as Visbiome® (V) and Met in preventing the ethanol‐induced hepatic injury using in vitro and in vivo models. Human HepG2 cells and male Wistar rats were exposed to ethanol and simultaneously treated with probiotic V or Met alone as well as in combination. Endoplasmic reticulum (ER) stress markers, inflammatory markers, lipid metabolism, reactive oxygen species (ROS) production, and oxidative stress were evaluated, using qRT‐PCR, Oil red O staining, fluorimetry, and HPLC. In vitro, probiotic V and Met in combination prevented ethanol‐induced cellular injury, ER stress, oxidative stress, and regulated lipid metabolism as well as inflammatory response in HepG2 cells. Probiotic V and Met also promoted macrophage polarization towards the M2 phenotype in ethanol‐exposed RAW 264.7 macrophage cells. In vivo, combined administration of probiotic V and Met ameliorated the histopathological changes, inflammatory response, hepatic markers (liver enzymes), and lipid metabolism induced by ethanol. It also improved the antioxidant markers (HO‐1 and Nrf‐2), as seen by their protein levels in both HepG2 cells as well as liver tissue using ELISA. Hence, probiotic V may act, in addition to the Met, as an effective preventive treatment against ethanol‐induced hepatic injury.

19 December 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
DPDhara Patel
Dhara Patel
CDChirayu Desai
Chirayu Desai
DSDeepmala Singh
Deepmala Singh
VSVirupakshi Soppina
Virupakshi Soppina
KPKirti Parwani
Kirti Parwani
PALASH MANDALPALASH MANDAL
PALASH MANDAL
Alcoholic liver disease (ALD) alters gut microbiota and tight junctions, causing bacterial components to enter the portal vein and induce oxidative stress-induced inflammation in the liver. Only corticosteroids and liver transplants are treatment options for severe alcoholic hepatitis. ALD’s pathophysiology is unknown. However, acetaldehyde’s toxic effects cause oxidative stress and intestinal permeability. This study investigates the influence of a synbiotic (a combination of aged garlic extract (AGE) and Lactobacillus rhamnosus MTCC1423) on colonic oxidative stress and inflammation in ALD male Wistar rats and Caco2 cells. MDA measurement by HPLC in CaCo2 cells, blood serum, and colon tissue demonstrated that synbiotic treatment in the ALD model reduces oxidative stress. Further, fecal high-throughput 16S rRNA gene sequencing revealed the microbiome’s shift towards Firmicutes in the synbiotic group compared to ethanol. In addition, DCFDA labeling and H/E staining demonstrate that the synbiotic is beneficial in inhibiting the development of ALD. In the colon, the synbiotic reduces the activation of CYP2E1 and the inflammatory markers TNF-a and IL-6 while elevating the mRNA expression of ZO-1, occludin, and IL-10. Synbiotics colonize Lactobacillus to restore barrier function and microbiota and reduce colon oxidative stress. Thus, a synbiotic combination can be used in ALD treatment.

7 May 2021 in Molecules
Verified
Journal Article
Open access
PDF file
KPKirti Parwani
Kirti Parwani
FPFarhin Patel
Farhin Patel
DPDhara Patel
Dhara Patel
PALASH MANDALPALASH MANDAL
PALASH MANDAL
Increased blood glucose in diabetic individuals results in the formation of advanced glycation end products (AGEs), causing various adverse effects on kidney cells, thereby leading to diabetic nephropathy (DN). In this study, the antiglycative potential of Swertiamarin (SM) isolated from the methanolic extract of E. littorale was explored. The effect of SM on protein glycation was studied by incubating bovine serum albumin with fructose at 60 °C in the presence and absence of different concentrations of swertiamarin for 24 h. For comparative analysis, metformin was also used at similar concentrations as SM. Further, to understand the role of SM in preventing DN, in vitro studies using NRK-52E cells were done by treating cells with methylglyoxal (MG) in the presence and absence of SM. SM showed better antiglycative potential as compared to metformin. In addition, SM could prevent the MG mediated pathogenesis in DN by reducing levels of argpyrimidine, oxidative stress and epithelial mesenchymal transition in kidney cells. SM also downregulated the expression of interleukin-6, tumor necrosis factor-α and interleukin-1β. This study, for the first time, reports the antiglycative potential of SM and also provides novel insights into the molecular mechanisms by which SM prevents toxicity of MG on rat kidney cells.

1 January 2021 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
FPFarhin Patel
Farhin Patel
KPKirti Parwani
Kirti Parwani
PRPriyashi Rao
Priyashi Rao
DPDhara Patel
Dhara Patel
RRRakesh M. Rawal
Rakesh M. Rawal
PALASH MANDALPALASH MANDAL
PALASH MANDAL
Ethanol depletes intestinal integrity and promotes gut dysbiosis. Studies have suggested the individual role of probiotics and metformin Met in protecting intestinal barrier function from injuries induced by ethanol. The objective of the current study is to investigate the potential mechanism by which coadministration of probiotic Visbiome® (V) and Met blocks the ethanol‐induced intestinal barrier dysfunction/gut leakiness utilizing Caco‐2 monolayers, a rat model with chronic ethanol injury, and in silico docking interaction models. In Caco‐2 monolayers, exposure to ethanol significantly disrupted tight junction (TJ) localization, elevated monolayer permeability, and oxidative stress compared with controls. However, cotreatment with probiotic V and Met largely ameliorated the ethanol‐induced mucosal barrier dysfunction, TJ disruption, and gut oxidative stress compared with ethanol‐exposed monolayers and individual treatment of either agent. Rats fed with ethanol‐containing Lieber‐DeCarli liquid diet showed decreased expression of TJ proteins, and increased intestinal barrier injury resulting in pro‐inflammatory response and oxidative stress in the colon. We found that co‐administration of probiotic V and Met improved the expression of intestinal TJ proteins (ZO‐1 and occludin) and upregulated the anti‐inflammatory response, leading to reduced ER stress. Moreover, co‐administration of probiotic V and Met inhibited the CYP2E1 and NOX gene expression, and increase the translocation of Nrf‐2 as well as anti‐oxidative genes (SOD, catalase, Gpx, and HO‐1), leading to reduced colonic ROS content and malondialdehyde levels. The combined treatment of probiotic V and Met also improved their binding affinities towards HO‐1, Nrf‐2, SLC5A8, and GPR109A, which could be attributed to their synergistic effect. Our findings based on in-vitro, in-vivo, and in-silico analyses suggest that the combination of probiotic V and Met potentially acts in synergism, attributable to their property of inhibition of inflammation and oxidative stress against ethanol‐induced intestinal barrier injury.

24 August 2026 in Journal of Biological Chemistry
Verified
Journal Article
Open access
RARathinam Ayyasamy
Rathinam Ayyasamy
JBJaya Bhandari
Jaya Bhandari
KPKirti Parwani
Kirti Parwani
HYHope LeeAnn York
Hope LeeAnn York
JMJenna McGowan
Jenna McGowan
Ritu ChakravartiRitu Chakravarti
Ritu Chakravarti